InxMed

InxMed is a clinical-stage to late clinical-stage oncology biotechnology company focused on overcoming tumor defense mechanisms and treatment resistance in solid tumors. The company operates in China and the United States and is advancing a differentiated pipeline spanning small molecules and antibody-drug conjugates. Its lead asset, ifebemtinib, is an oral focal adhesion kinase inhibitor in registrational development and has received Breakthrough Therapy Designation from China NMPA and Fast Track Designation from the U.S. FDA. InxMed is also developing OMTX705, a fibroblast activation protein-targeting antibody-drug conjugate for stroma-rich tumors, alongside additional preclinical programs. The company positions its discovery and translational capabilities around key nodes in the tumor microenvironment and resistance biology to improve efficacy across combination regimens.